Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873205 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Blood Cancer and Refractory Immune Cytopenias, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT05873205: Recruiting Phase 2 study of Blood Cancer and Refractory Immune Cytopenias, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05873205 is a Phase 2 study of Blood Cancer and Refractory Immune Cytopenias that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 264-participant average among 12 other Blood Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05873205, a Phase 2 study of Blood Cancer and Refractory Immune Cytopenias, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Primary Outcome
To estimate the overall response rate (ORR; complete response \[CR\] + response)
Conditions Studied
Interventions
- BIOLOGICAL Isatuximab
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2026-06-29 |
| Phase | Phase 2 |
What NCT05873205 shows while recruiting
NCT05873205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 264-participant average among 12 other Blood Cancer trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Blood Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isatuximab is the first listed.
NCT05873205 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05873205 about?
NCT05873205 is a clinical study titled "Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation". The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
What is the current status of trial NCT05873205?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-07-21. Estimated completion is 2026-06-29.
What conditions does trial NCT05873205 study?
This clinical trial studies the following conditions: Blood Cancer, Refractory Immune Cytopenias.
What interventions are being tested in trial NCT05873205?
The interventions under investigation include: Isatuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05873205?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05873205 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05873205's enrollment target sits among peer trials
12 13th of 12 the lowest of 12 other Blood Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Pharmacogenomics for Better Treatment of Fungal Infections in Cancer
RECRUITING · Phase 2
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI